IDWeek 2026：olorofim 在二线侵袭性曲霉病治疗中显示潜力

IDWeek 2026: olorofim shows promise in second-line invasive aspergillosis

AI 导读

IDWeek 2026 公布的数据显示，olorofim 在二线侵袭性曲霉病（IA）治疗中结果积极，尤其在肾脏安全性方面表现突出。作为口服给药、较 AmB 更安全的替代选择，olorofim 有望于 2027 年获得 FDA 批准用于 IA。目前 mould-active azole antifungals（MAAs）仍是 IA 的标准治疗（SOC）。

正文 · 原文

Overall, the findings of the trial are promising, particularly in relation to renal safety. Given the urgent need for an orally administered, safer alternative to AmB, olorofim has strong potential to receive FDA approval for IA in 2027.

Mould-active azole antifungals (MAAs) remain the SOC for the treatment of IA. Credit: Fahroni via Shutterstock.com.

Unlock FREE Access to Premium Content

Discover exclusive forecasts, analyst insights, and in-depth clinical trials industry analysis across drug development, clinical research, and trial innovation.

With a free Clinical Trials Arena profile, you can:

Access exclusive analyst commentary and expert insights
View premium forecasts and data-driven clinical trial intelligence
Stay up to date with clinical trial news, regulatory updates, and industry trends
Receive alerts when new premium content is published

Unlock free access

Already have an account? Login here

来源：Clinical Trials Arena · clinicaltrialsarena.com

IDWeek 2026：olorofim 在二线侵袭性曲霉病治疗中显示潜力

Unlock FREE Access to Premium Content

​Discover exclusive forecasts, analyst insights, and in-depth clinical trials industry analysis across drug development, clinical research, and trial innovation.

Unlock free access

Discover exclusive forecasts, analyst insights, and in-depth clinical trials industry analysis across drug development, clinical research, and trial innovation.